Semaglutide
Also known as: Semaglutide (GLP-1 agonist)
Semaglutide is a GLP-1 receptor agonist used for type 2 diabetes management and chronic weight management. It mimics the incretin hormone GLP-1 to regulate appetite and glucose metabolism.
Who's worth your money for Semaglutide
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (99) of 9 scored sellers
$976 · 200mg · 99.9% purity
Best value
Lowest $/mg among scored sellers
$10.00 · 10mg
Most tested
12 independent COAs on file
$153 · 20mg · 99.3% purity
Average price
$9.25/mg
Sellers
62
45-day trend
+26%
53 of 62 sellers have a current price· 40 stale hidden· 4 unverified hidden
Top Merit pick
🇺🇸 Peptide Partners99via Disclosed Labs · 23h ago
$4.88/mg -47.2% vs avg$976
200mg
- 🇺🇸 Profound Aminos95
via Disclosed Labs · 23h ago
$7.65/mg -17.3% vs avg$153
20mg
- 🇺🇸 Prime Peptides95
via Disclosed Labs · 23h ago
$8.67/mg -6.3% vs avg$130
15mg
- 🇨🇳 Reta Peptide83
✓ verified at source · 23h ago
$6.50/mg -29.7% vs avg$65.00
10mg
- 🇺🇸 Blank Peptides81
via Disclosed Labs · 23h ago
$5.31/mg -42.6% vs avg$425
80mg
- 🇺🇸 OROS Research79
via Disclosed Labs · 3d ago
$9.00/mg -2.7% vs avg$89.99
10mg
- 🇺🇸 Texpeptide69
✓ verified at source · 23h ago
$7.50/mg -18.9% vs avg$150
20mg
no purity - 🇭🇰 Hkuppeptide50
✓ verified at source · 23h ago
$1.00/mg -89.2% vs avg$10.00
10mg
no purity - 🇭🇰 zztai Peptide Ltd43
✓ verified at source · 23h ago
$3.87/mg -58.2% vs avg$116
30mg
no purity
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch Semaglutide
Get one email when the market actually moves — no newsletter, no noise.
About Semaglutide
CAS
910463-68-2
Molecular formula
C187H291N45O59
Typical dose range
0.25–2.4 mg (250–2400 mcg) subcutaneous once weekly; typically titrated from 0.25 mg/week, increasing every 4 weeks
Half-life
~7 days
COAs for Semaglutide
153 third-party tests across 20 vendors. Each card links to the full report.
For
Semaglutide
by Peptide Partners· batch SPL-4149
For
Semaglutide
by Peptide Plugs· batch 125-01-SM
For
Semaglutide
by EZ Peptides· batch EZP-1P1005102026-03
For
Semaglutide
by EZ Peptides· batch EZP-1P1005102026-03
For
Semaglutide
by Pepsgpt· batch P-2885342-P
For
Semaglutide
by Prime Peptides· batch 3022026SM
For
Semaglutide
by Prime Peptides· batch 3142026SM
For
Semaglutide
by Prime Peptides· batch 2242026SM
For
ION-1S
by Ion Peptide· batch ION1S20-04172026
For
Semaglutide
by OROS Research· batch OR-LPGLPS10-426-B3
For
Semaglutide
by Prime Peptides· batch 3272026SM
For
Semaglutide
by Prime Peptides· batch 3222026SX
For
Semaglutide
by Blank Peptides· batch 665394
For
Semaglutide
by Prime Peptides· batch 2182026SM
For
Semaglutide
by Prime Peptides· batch 2122026SM
For
Semaglutide
by Orbitrex Peptides· batch 1G200426
For
Semaglutide
by Qihang Peptide· batch 3
For
Semaglutide
by Reta One Labs· batch SM100326
For
Semaglutide
by Reta One Labs· batch SM200326
For
Semaglutide
by EZ Peptides· batch EZP-1P0502152026-01
For
Semaglutide
by EZ Peptides· batch EZP-1P0502152026-01
For
Semaglutide
by Reta One Labs· batch SM100326
For
Semaglutide
by Reta One Labs· batch SM200326
For
Semaglutide
by Prime Peptides· batch 1052026SM
23 citations indexed for Semaglutide
Study · 2026
Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial
Background This phase 2 study evaluated once-weekly zalfermin and semaglutide for efficacy and safety in patients with metabolic dysfunction-associated steatohepatitis and clinically significant fibrosis, including patients with compensated cirrhosis (F4c).
cohort · 2026
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study
Background To compare sleeve gastrectomy, semaglutide therapy, and the Diet, Exercise, Accompany and Refresh (DEAR) weight management programme for weight control, metabolic improvement, and oncological outcomes in patients with endometrial cancer receiving fertility-sparing treatment.
Study · 2026
Impact of semaglutide on cognitive function in patients with type 2 diabetes and mild cognitive impairment: a 24-month observational study
Type 2 diabetes mellitus (T2DM) is associated with an increased risk of mild cognitive impairment (MCI) and dementia. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) provide cardiovascular and metabolic benefits, and emerging data suggest neurocognitive effects.
animal · 2026
Semaglutide and Exercise Synergy in Obesity: Preserving Muscle Mass and Uncovering Organ Crosstalk
Background Semaglutide, a glucagon-like peptide-1 receptor agonist, effectively promotes weight loss and improves metabolic parameters in individuals with obesity. However, its use is often accompanied by reductions in lean mass, raising concerns about long-term muscle health.
review · 2026
Advances in proteomics research related to semaglutide: evidence from humans and animals
Background With the advancement of proteomics technologies, an increasing number of studies have begun to examine semaglutide-associated protein expression changes and pathway alterations across different biological contexts.
cohort · 2026
Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials
Background Obesity is a chronic, progressive disease affecting over 1 billion adults worldwide, linked to serious comorbidities, including diabetes, hypertension, and cardiovascular disease and associated with increased mortality. Achieving clinically meaningful weight loss is critical to reducing cardiometabolic risk.